H.C. Wainwright cuts NovoCure stock price target to $32 on valuation By Investing.com
H.C. Wainwright cut its NovoCure Ltd. (NASDAQ:NVCR) price target to $32 from $46 but kept a Buy rating. NVCR trades around $19.99. The firm cited NovoCure’s Q2 2026 revenue of $183.6M and updated 2026 revenue guidance to $710M-$725M, with adjusted EBITDA guidance revised to $0-$15M.
How this was made
The 30-second read
Why it matters
The main tradable input is the analyst’s price target reduction, which can influence short-term flows and expectations. The company-specific numbers cited (revenue and adjusted EBITDA guidance revisions) provide fundamental support but are presented as context within the analyst note.
Market read
A PT cut with a maintained Buy rating suggests valuation caution, but the cited guidance revisions and commercial momentum temper the bearish read-through.
What to watch
Traders may overweight the PT reduction while underweighting the specific guidance components (Optune Lua/Pax launch and reimbursements) that could sustain upside if execution continues.
Background
The piece centers on an H.C. Wainwright valuation update for NovoCure, alongside a recap of the company’s 2Q results and 2026 guidance revisions.
Ticker impact
H.C. Wainwright cut NovoCure’s price target to $32 from $46 while keeping a Buy rating, citing valuation despite guidance revisions.
Likely supports downside trimming or stabilization rather than a fresh fundamental repricing, unless traders treat the PT cut as a signal on valuation risk.
The article’s actionable change is the analyst PT reduction, while the underlying company updates (revenue and EBITDA guidance revisions) are supportive but not newly disclosed in this text beyond the analyst framing.
Market effects
Could modestly affect sentiment toward oncology device and tumor-treating-fields peers by reinforcing valuation sensitivity despite improving profitability trajectory.
Limited, as the catalyst is an analyst action on a US-listed name.
Low, NovoCure’s guidance includes international markets but the immediate driver is a US analyst PT change.
Counterpoint
The PT cut may be more about valuation math than deteriorating fundamentals, especially since the company revised revenue guidance upward and moved adjusted EBITDA toward positive.
Key entities
- companyNovoCure Ltd.
NASDAQ-listed tumor treating fields company whose price target was cut to $32 from $46 by H.C. Wainwright.
- analyst_firmH.C. Wainwright
Maintained a Buy rating while lowering the NovoCure price target, implying valuation compression risk.
